Topical Avastin for Treatment of Corneal Neovascularization
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00559936|
Recruitment Status : Completed
First Posted : November 16, 2007
Results First Posted : September 24, 2012
Last Update Posted : October 5, 2012
|Condition or disease||Intervention/treatment||Phase|
|Corneal Neovascularization||Drug: Topical Avastin 1%||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization|
|Study Start Date :||February 2007|
|Actual Primary Completion Date :||October 2010|
|Actual Study Completion Date :||October 2010|
Experimental: Topical Avastin 1.0%
Each patient will receive topical Avastin in one eye.
Drug: Topical Avastin 1%
Avastin (bevacizumab) 1%
Other Name: bevacizumab
- The Size and Extent of Corneal Neovascularization Will be Measured by Computerized Image Analysis of Corneal Photographs Taken Throughout the Study. [ Time Frame: Six Months ]The efficacy of bevacizumab in the treatment of corneal NV was evaluated by comparing corneal photographs taken at baseline with corneal photographs taken at the follow-up visits. Percent change from baseline was measured.
- Ocular and Systemic Safety [ Time Frame: All study visits ]The occurrence of ocular and systemic adverse events was closely monitored over the course of this study. Ocular adverse events were monitored through complete ocular examinations including visual acuity measurement, intraocular pressure measurement, biomicroscopy, and corneal fluorescein staining. Systemic adverse events were identified with physical examinations, patient questioning, and blood pressure measurements taken throughout the study period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00559936
|United States, Massachusetts|
|Massachusetts Eye and Ear Infirmary|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Reza Dana, M.D., MPH||Massachusetts Eye and Ear Infirmary|